RT Journal Article
SR Electronic
T1 Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000798corr1
DO 10.1136/jitc-2020-000798corr1
VO 8
IS 1
YR 2020
UL http://jitc.bmj.com/content/8/1/e000798corr1.abstract